Cilostazol ameliorates warfarin-induced hemorrhagic transformation after cerebral ischemia in mice

Stroke

Volumn 44, Issue 10, 2013, Pages 2862-2868

  Kitashoji, Akira ^a   Egashira, Yusuke ^a   Mishiro, Keisuke ^a   Suzuki, Yukiya ^a   Ito, Hideki ^b   Tsuruma, Kazuhiro ^a   Shimazawa, Masamitsu ^a   Hara, Hideaki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Anticoagulants; Cilostazol; Hemorrhage; Mice; Stroke; Warfarin

Indexed keywords

CILOSTAZOL; GELATINASE A; GELATINASE B; HEMOGLOBIN; TIGHT JUNCTION PROTEIN; VASCULAR ENDOTHELIAL CADHERIN; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BLEEDING TIME; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN LEVEL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; ENDOTHELIUM CELL; HEMORRHAGIC TRANSFORMATION; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTHROMBIN TIME; REPERFUSION; SURVIVAL RATE; SWELLING; TREATMENT DURATION; UPREGULATION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ANTICOAGULANTS; CILOSTAZOL; HEMORRHAGE; MICE; STROKE; WARFARIN;

ANIMALS; ANTICOAGULANTS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; ENDOTHELIUM, VASCULAR; MALE; MICE; PHOSPHODIESTERASE 3 INHIBITORS; TETRAZOLES; TIGHT JUNCTIONS; TIME FACTORS; WARFARIN;

EID: 84888371010     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.001183     Document Type: Article

References (33)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Med Assoc. 2001, 285:2370-2375.
2. Go AS. The epidemiology of atrial fibrillation in elderly persons: The tip of the iceberg. Am J Geriatr Cardiol. 2005, 14:56-61.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007, 146:857-867.
4. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al, American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011, 42:227-276.
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009, 361:1139-1151.
6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011, 365:883-891.
7. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke. 2006, 37:256-262.
8. Paciaroni M, Agnelli G, Corea F, Ageno W, Alberti A, Lanari A, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke. 2008, 39:2249-2256.
9. Lee JH, Kim KY, Lee YK, Park SY, Kim CD, Lee WS, et al. Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats. J Pharmacol Exp Ther. 2004, 308:896-903.
10. Nonaka Y, Tsuruma K, Shimazawa M, Yoshimura S, Iwama T, Hara H. Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage. Neurosci Lett. 2009, 452:156-161.
11. Pfeilschifter W, Spitzer D, Czech-Zechmeister B, Steinmetz H, Foerch C. Increased risk of hemorrhagic transformation in ischemic stroke occurring during warfarin anticoagulation: An experimental study in mice. Stroke. 2011, 42:1116-1121.
12. Ishiguro M, Mishiro K, Fujiwara Y, Chen H, Izuta H, Tsuruma K, et al. Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. PLoS One. 2010, 5:e15178.
13. Ishiguro M, Suzuki Y, Mishiro K, Kakino M, Tsuruma K, Shimazawa M, et al. Blockade of phosphodiesterase-III protects against oxygen-glucose deprivation in endothelial cells by upregulation of VE-cadherin. Curr Neurovasc Res. 2011, 8:86-94.
14. Oyama N, Yagita Y, Kawamura M, Sugiyama Y, Terasaki Y, Omura- Matsuoka E, et al. Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats. Stroke. 2011, 42:2571-2577.
15. Foerch C, Arai K, Jin G, Park KP, Pallast S, van Leyen K, et al. Experimental model of warfarin-associated intracerebral hemorrhage. Stroke. 2008, 39:3397-3404.
16. Hara H, Huang PL, Panahian N, Fishman MC, Moskowitz MA. Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. J Cereb Blood Flow Metab. 1996, 16:605-611.
17. Molina CA, Alvarez-Sabín J, Montaner J, Abilleira S, Arenillas JF, Coscojuela P, et al. Thrombolysis-related hemorrhagic infarction: A marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke. 2002, 33:1551-1556.
18. Dzialowski I, Pexman JH, Barber PA, Demchuk AM, Buchan AM, Hill MD, CASES Investigators. Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type in the Canadian Alteplase For Stroke Effectiveness Study Registry. Stroke. 2007, 38:75-79.
19. Schwammenthal Y, Bornstein N, Schwammenthal E, Schwartz R, Goldbourt U, Tsabari R, et al. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey [NASIS]). Am J Cardiol. 2010, 105:411-416.
20. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003, 349:1019-1026.
21. Indredavik B, Rohweder G, Lydersen S. Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation. J Intern Med. 2005, 258:133-144.
22. O'Donnell M, Oczkowski W, Fang J, Kearon C, Silva J, Bradley C, et al, Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: An observational study. Lancet Neurol. 2006, 5:749-754.
23. Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, et al, Cilostazol Versus Aspirin for Secondary Ischaemic Stroke Prevention Cooperation Investigators. Cilostazol as an alternative to aspirin after ischaemic stroke: A randomised, double-blind, pilot study. Lancet Neurol. 2008, 7:494-499.
24. Uchiyama S, Demaerschalk BM, Goto S, Shinohara Y, Gotoh F, Stone WM, et al. Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis. 2009, 18:482-490.
25. Kim JS, Lee KS, Kim YI, Tamai Y, Nakahata R, Takami H. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: Analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci. 2004, 11:600-602.
26. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, et al, CSPS 2 Group. Cilostazol for prevention of secondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomised noninferiority trial. Lancet Neurol. 2010, 9:959-968.
27. Kim KY, Shin HK, Choi JM, Hong KW. Inhibition of lipopolysaccharide- induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther. 2002, 300:709-715.
28. Hara H, Friedlander RM, Gagliardini V, Ayata C, Fink K, Huang Z, et al. Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA. 1997, 94:2007-2012.
29. Nonaka Y, Koumura A, Hyakkoku K, Shimazawa M, Yoshimura S, Iwama T, et al. Combination treatment with normobaric hyperoxia and cilostazol protects mice against focal cerebral ischemia-induced neuronal damage better than each treatment alone. J Pharmacol Exp Ther. 2009, 330:13-22.
30. Akiyama H, Kudo S, Shimizu T. The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man. Arzneimittelforschung. 1985, 35(7A):1124-1132.
31. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab. 1998, 18:1163-1172.
32. Kelly PJ, Morrow JD, Ning M, Koroshetz W, Lo EH, Terry E, et al. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: The Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) Study. Stroke. 2008, 39:100-104.
33. Mallikaarjun S, Bramer SL. Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin. Clin Pharmacokinet. 1999, 37(suppl 2): 79-86.